Rationale for current and future progestin-based therapies to prevent preterm birth

Area of Science:

• Reproductive biology
• Maternal-fetal medicine
• Pharmacology

Background:

• Preterm birth (PTB) is a major global cause of newborn illness and death.
• Current therapies like micronized progesterone and 17α-hydroxyprogesterone caproate reduce PTB risk in specific high-risk groups.
• The exact mechanisms by which progestins prevent PTB are not fully understood.

Purpose of the Study:

• To investigate the molecular mechanisms of progesterone (P4) signaling in uterine cells.
• To identify novel therapeutic targets for improving PTB prevention strategies.
• To enhance the effectiveness of progestin therapy for a broader range of pregnancies.

Main Methods:

• Analysis of P4 signaling pathways via P4 receptor isoforms in uterine cells.
• Exploration of molecular biology and physiology related to progesterone action.
• Focus on pathways involved in inflammation-induced parturition.

Main Results:

• Advances in understanding P4 signaling pathways have been achieved.
• Novel therapeutic targets for PTB prevention have been identified.
• Potential for improving progestin therapy effectiveness is suggested.

Conclusions:

• Understanding P4 signaling offers new avenues for PTB prevention.
• Targeting key steps in inflammation-induced parturition may enhance therapy.
• Future strategies could improve PTB prevention for the majority of pregnancies.